04.08.24 -- Biopharma In Developing Countries

Explore how early access programs are tailored to individual sufferers of rare, ultra-rare, or life-threatening conditions, as well as cohort programs, which target groups of patients afflicted with the same disease.

Explore the challenges behind the perceived simplicity of mRNA process development, as well as characterization strategies and models for predicting process outcomes at early stages.

One of the primary obstacles hindering participation in clinical trials is the financial burden. Learn how to strengthen and globalize participant convenience programs by removing logistical and financial barriers.

Innovations in drug delivery formats are enabling more patient-centric treatments and helping to boost patient compliance. Learn about the advances being developed to expand the potential of ODT technology.

A clear path for establishing equivalency is needed to facilitate more rapid advances in the gene therapy field and ultimately to enable lower-cost gene therapies that reach patients faster than ever.